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    NAFLD: Non-Alcoholic Fatty Liver Disease; MAFLD: Metabolic Associated Fatty Liver Disease; NASH: Non-
Alcoholic Steatohepatitis 
 
    As the prevalence of obesity and type 2 diabetes 
mellitus (T2DM) has been increasing worldwide, fatty 
liver disease from metabolic dysfunction has been a 
global medical and health problem [1]. Especially, it 
was observed in early stages preceding the T2DM 
development. The problems among fatty liver, T2DM, 
metabolic syndrome have been important. Further, 
diagnostic criteria of non-alcoholic fatty liver disease 
(NAFLD) was common for usual practice of medicine 
[2]. 
    NAFLD has affected approximately one quarter of 
adult population across the world, and brought 
medical, health and economic burden to many societies 
[2,3]. The effective pharmacotherapy for NAFLD has 
not been approved until now [4]. Higher NAFLD 
prevalence would be from several elements, such as 
excess carbohydrate intake, elevated calorie energy 
intake, decreased physical activity, habit of sedentary 
behavior, imbalance of diet and exercise, and so on [5]. 
Along with this tendency, health situation of  adult  has  
Abstract 
    The problems among obesity, diabetes mellitus (DM), fatty liver, metabolic dysfunction have been 
prevalent, and diagnostic criteria as non-alcoholic fatty liver disease (NAFLD) has been used in practice. When 
diagnosing NAFLD, to exclude other related liver diseases was necessary, including excessive alcohol intake. 
The international experts proposed the proper term from NAFLD to metabolic associated fatty liver disease 
(MAFLD). MAFLD criteria include the evidence of the presence of hepatic steatosis associated with three 
situations. They are obesity/overweight, presence of Type 2 DM (T2DM), or metabolic impaired function, 
which were studied in the light of pathophysiology, epidemiology, diagnosis and pharmacotherapy. 
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been not satisfactory, even if the adult shows normal 
BMI in the affluent country [6,7].  
 
    NAFLD has recently shown higher ratio of the cause 
for chronic liver disease [2]. Regarding NAFLD in most 
guidelines, it is defined for the evidence of steatosis in 
5%< of existing hepatocytes by medical imaging 
and/or histological examination [8]. Furthermore, it is 
important to show the situation of the absence in 
several causes including alcohol, B or C type of viral 
hepatitis, some kinds of hereditary liver diseases, or 
steatogenic medication for long term [9]. 
 
    This diagnostic way has been adopted as an 
exclusive method, and for which liver biopsy would be 
the golden standard. It covers a spectrum for 
progressive liver diseases including steatosis to 
fibrosis, cirrhosis, nonalcoholic steatohepatitis (NASH) 
and hepatocellular carcinoma (HCC) [10]. It was well-
known that it is clearly associated with metabolic 
dysfunction, where several components co-exist for 
abdominal obesity, hypertension, dyslipidemia and 
hyperglycemia [11]. As the existing ratio of NAFLD 
grows dramatically, there are urgent clinical problems 
[12]. They include i) the absence of clear nomenclature 
of the fatty liver due to non-alcohol use, ii) the lack of 
positive diagnosis with proper definition, iii) no 
approved medical agents for this disease, etc.  
 
    From statistic point of view, NAFLD has been found 
about 25% of the population worldwide [2,3]. 
According to the previous data, diabetics have chronic 
liver disease associated with about three-fold higher 
risk, which is mainly from non-alcohol or non-virus 
etiology leading to NAFLD [13]. NAFLD prevalence in 
T2DM shows up to 55.5%, which is more than twice 
than general people [14].  A recent meta-analysis data 
showed the prevalence of NAFLD as follows: general 
people 29.8%, T2DM 51.8%, non-diabetic 30.7%, 
obesity 66.2% and lean 11.7% [15].  As obesity shows 
rising trend from 2%-7% in 2000-2014, NAFLD 
showed increase in parallel [16]. Further, obesity and 
T2DM showed the elevated risk of progression for 
NASH, cirrhosis and HCC [17,18]. Consequently, 
growing epidemic situation of obesity and T2DM will 
bring increasing prevalence for NAFLD across the 
world [19].  
 
 
    Related to NAFLD, a panel of international experts 
was gathered from 22 countries [3]. The experts have 
proposed a changing medical term from NAFLD to new 
medical term, which is metabolic associated fatty liver 
disease (MAFLD). They reached a consensus that the 
term NAFLD would not reflect proper knowledge and 
that MAFLD would be more appropriate from 
terminological point of view. The new definition of 
MAFLD puts emphasis on the important function from 
metabolic aspect. In comparison with former NAFLD, 
newly summarized definition of MAFLD is supposed to 
include wider perspective. MAFLD criteria showed the 
evidence of hepatic steatosis found with the following 
three situations. They are obesity/overweight, T2DM 
presence, and/or the evidence of metabolic dysfunction 
(dysregulation) [20]. There are some differences of 
shared features between the words of NAFLD and 
MAFLD, in the light of pathophysiology, epidemiology, 
diagnosis and pharmacotherapy. 
 
    Similar to previous medical term NAFLD, MAFLD 
has represents hepatic manifestation for multisystem 
disorder. It shows heterogeneous factors in underlying 
cause, symptom and signs, clinical outcomes and 
progress course [13]. However, due to the complex 
pathophysiological aspects, a single diagnostic test is 
not likely to be available. Metabolic syndrome contains 
some definitions, and it seems necessary to develop the 
new criteria for diagnosing MAFLD in this way [21,22].  
 
    When diagnosing MAFLD, to exclude the other 
chronic liver diseases is necessary, including excessive 
alcohol intake [23]. With the elucidation of the 
pathophysiological processes causing to MAFLD, it 
would be increasingly understood that the existence of 
generalized metabolic syndrome seems to exist at the 
fundamental level. As a result, MAFLD is recognized 
for an independent disease that guarantees a positive 
diagnostic process, rather than excluding other 
diseases. Furthermore, the prevalence of MAFLD has 
been elevated, which makes it possible to exist in 
combination of other chronic liver diseases. Therefore, 
the method of excluding comorbidities becomes 
inappropriate. From the above, MAFLD definition will 
be made not according to the exclusion criteria but 
from the set of additional positive criteria [3]. 
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    Regarding the proposal from the experts, the disease 
assessment and stratification of MAFLD severity 
should cover the wider area, which are beyond a 
simple dichotomous classification of non-
steatohepatitis and steatohepatitis [20]. There are 
other proposals including a set of criteria for the 
definition of MAFLD associated liver cirrhosis, and a 
conceptual perspective for other possible causes for 
fatty live. Consequently, the distinction would be 
clarified for the distinction of diagnostic criteria and 
also the inclusion criteria for research and clinical 
trials. To reaching a certain consensus on MAFLD 
criteria will contribute the unification of the medical 
terms including the International Classification of 
Diseases (ICD)-coding, Disease-Related Groups (DRG), 
verification of clinical trials, development of liver 
research and the improvement of clinical care [20]. 
 
    In summary, current topics concerning the changing 
term from NAFLD to MAFLD were described in this 
article. Some clinical trials are found concerning the 
inclusion criteria and endpoints [24]. Such studies will 
bring various initiatives evolving for clinical 
application of new nomenclature MAFLD definition. 
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